International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), Journal of Thrombosis and Haemostasis, vol.75, issue.2, pp.295-306, 2006. ,
DOI : 10.1093/ajcp/103.1.103
Antiphospholipid syndrome, The Lancet, vol.376, issue.9751, pp.1498-509, 2010. ,
DOI : 10.1016/S0140-6736(10)60709-X
The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome, New England Journal of Medicine, vol.332, issue.15, pp.993-1000, 1995. ,
DOI : 10.1056/NEJM199504133321504
Toll-Like Receptor Pathways in Autoimmune Diseases, Clinical Reviews in Allergy & Immunology, vol.34, issue.Suppl 1, pp.1-17, 2016. ,
DOI : 10.1002/eji.200324174
Toll-like receptors 4 contribute to endothelial injury and inflammation in hemorrhagic shock in mice, Critical Care Medicine, vol.37, issue.5, pp.1724-1732, 2009. ,
DOI : 10.1097/CCM.0b013e31819da805
Role of Toll-like Receptors 2 and 4 in Mediating Endothelial Dysfunction and Arterial Remodeling in Primary Arterial Antiphospholipid Syndrome, Arthritis & Rheumatology, vol.164, issue.11, 2014. ,
DOI : 10.1111/bjh.12587
Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies, Annals of the Rheumatic Diseases, vol.66, issue.10, pp.1327-1360, 2007. ,
DOI : 10.1136/ard.2006.065037
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994302/pdf
TLR4 mutations are associated with endotoxin hyporesponsiveness in humans, Nat Genet, vol.25, issue.2, pp.187-91, 2000. ,
The anticardiolipin syndrome, J Rheumatol, 1986. ,
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop, Arthritis & Rheumatism, vol.7, issue.7, 1999. ,
DOI : 10.1191/096120398678919624
Quelle est la nature des lésions vasculaires du syndrome des antiphospholipides? Rev Médecine Interne, pp.476-80, 1993. ,
DOI : 10.1016/s0248-8663(05)80415-1
The Antiphospholipid Syndrome, New England Journal of Medicine, vol.346, issue.10, pp.752-63, 2002. ,
DOI : 10.1056/NEJMra002974
Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients, Arthritis & Rheumatism, vol.15, issue.suppl 7, pp.1019-1046, 2002. ,
DOI : 10.1006/jaut.2000.0423
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients, Annals of the Rheumatic Diseases, vol.82, issue.(Suppl 7), pp.1011-1019, 2015. ,
DOI : 10.1097/01.md.0000091181.93122.55
The catastrophic antiphospholipid syndrome, J Rheumatol, 1992. ,
Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome, Annals of the Rheumatic Diseases, vol.64, issue.8, pp.1205-1214, 2005. ,
DOI : 10.1136/ard.2004.025759
Catastrophic antiphospholipid syndrome: Updated diagnostic algorithms, Autoimmunity Reviews, vol.10, issue.2, pp.74-83, 2010. ,
DOI : 10.1016/j.autrev.2010.08.005
review on catastrophic antiphospholipid syndrome]. Presse Medicale Paris Fr 1983, pp.1084-92, 2016. ,
Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry, Autoimmunity Reviews, vol.15, issue.12, pp.1120-1124, 2016. ,
DOI : 10.1016/j.autrev.2016.09.010
Pathophysiology of the antiphospholipid syndrome (APS) Rev Med Interne, pp.2-4, 2012. ,
Pathophysiology of the antiphospholipid antibody syndrome. Auto- Immun Highlights, pp.35-52, 2011. ,
The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and ??2 glycoprotein 1 (and other proteins), Proceedings of the National Academy of Sciences, vol.93, issue.16, pp.10356-61, 1997. ,
DOI : 10.1073/pnas.93.16.8606
Endothelial cell activation by antiphospholipid antibodies, Clinical Immunology, vol.112, issue.2, pp.169-74, 2004. ,
DOI : 10.1016/j.clim.2004.02.015
Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-??2 glycoprotein I antibodies, Blood, vol.105, issue.5, pp.1964-1973, 2005. ,
DOI : 10.1182/blood-2004-05-1708
URL : http://www.bloodjournal.org/content/bloodjournal/105/5/1964.full.pdf
Beta2-glycoprotein I and LDL-receptor family members, Thromb Res, vol.114, pp.5-6455, 2004. ,
-glycoprotein I with members of the low density lipoprotein receptor family, Journal of Thrombosis and Haemostasis, vol.22, issue.8, pp.1680-90, 2006. ,
DOI : 10.1074/jbc.M405608200
Endothelium activation in the anti-phospholipid syndrome, Biomed Pharmacother Biomedecine Pharmacother, 2003. ,
DOI : 10.1016/S0753-3322(03)00083-0
The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood, Feb, vol.15109, issue.4, pp.1507-1521, 2007. ,
Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies, Annals of the Rheumatic Diseases, vol.66, issue.10, pp.1327-1360, 2007. ,
DOI : 10.1136/ard.2006.065037
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994302/pdf
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study, The Lancet Neurology, vol.8, issue.11, 2009. ,
DOI : 10.1016/S1474-4422(09)70239-X
Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid, Blood, vol.88, issue.11, pp.4173-82, 1996. ,
Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses, Thromb Haemost, vol.85, issue.5, pp.800-805, 2001. ,
NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)- glycoprotein 1 antibodies, Thromb Haemost, vol.88, issue.5, pp.851-858, 2002. ,
Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies, Arthritis & Rheumatism, vol.279, issue.5, pp.1545-54, 2005. ,
DOI : 10.1016/S0002-9378(12)90915-1
Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies, Blood, vol.101, issue.9, pp.3495-500, 2003. ,
DOI : 10.1182/blood-2002-08-2349
Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis, Arthritis & Rheumatism, vol.44, issue.1, pp.55-64, 2000. ,
DOI : 10.1038/ki.1993.315
Thrombogenic Effects of Antiphospholipid Antibodies Are Mediated by Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and P-Selectin, Circulation Research, vol.88, issue.2, pp.245-50, 2001. ,
DOI : 10.1161/01.RES.88.2.245
Tissue factor in the antiphospholipid syndrome, Lupus, vol.110, issue.10, pp.952-960, 2008. ,
DOI : 10.1161/01.CIR.0000136027.98303.4D
IL-2, IL-6 and TNF levels in primary antiphospholipid syndrome, Clin Exp Rheumatol, vol.10, issue.5, p.503, 1992. ,
Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood, Feb, vol.15109, issue.4, pp.1490-1494, 2007. ,
Autoantibodies against the fibrinolytic receptor, antiphospholipid syndrome. Blood, pp.4375-82, 2006. ,
DOI : 10.1182/blood-2005-07-2636
URL : http://www.bloodjournal.org/content/bloodjournal/107/11/4375.full.pdf
Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome, British Journal of Haematology, vol.5, issue.2, pp.375-384, 2001. ,
DOI : 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.02923.x/pdf
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, vol.101, issue.5, pp.1827-1859, 2003. ,
DOI : 10.1182/blood-2002-02-0441
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, vol.118, issue.17, pp.4714-4722, 2011. ,
DOI : 10.1182/blood-2011-03-340232
Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis, Autoimmunity Reviews, vol.15, issue.3, pp.203-212, 2016. ,
DOI : 10.1016/j.autrev.2015.11.001
Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis, Lupus, vol.333, issue.1, pp.15-22, 1998. ,
DOI : 10.1056/NEJM199509073331016
Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy, The American Journal of Medicine, vol.104, issue.4, pp.332-340, 1998. ,
DOI : 10.1016/S0002-9343(98)00060-6
Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study, Lupus, vol.86, issue.14, pp.1468-76, 2014. ,
DOI : 10.1055/s-0029-1242716
Antiphospholipid antibodies and thrombosis: do test patterns identify the patients' risk?, Thrombosis Research, vol.114, issue.5-6, pp.5-6597, 2004. ,
DOI : 10.1016/j.thromres.2004.08.009
Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ???seronegative APS???), Annals of the Rheumatic Diseases, vol.71, issue.2, pp.242-246, 2012. ,
DOI : 10.1136/annrheumdis-2011-200614
Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies, BMJ, vol.330, issue.7491, p.565, 2005. ,
DOI : 10.1136/bmj.38380.674340.E0
Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset, BMC Pregnancy and Childbirth, vol.100, issue.1, p.11, 2009. ,
DOI : 10.1016/S0029-7844(02)02165-8
Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis, J Rheumatol, vol.33, issue.11, pp.2214-2235, 2006. ,
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study, Rheumatology, vol.50, issue.9, pp.1684-1693, 2011. ,
DOI : 10.1093/rheumatology/ker139
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies, Lupus, vol.1173, issue.2, pp.206-224, 2011. ,
DOI : 10.1111/j.1538-7836.2009.03588.x
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody???positive individuals, Arthritis & Rheumatism, vol.113, issue.7, pp.2382-91, 2007. ,
DOI : 10.1136/bmj.309.6963.1215
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies, Autoimmunity Reviews, vol.14, issue.3, pp.192-200 ,
DOI : 10.1016/j.autrev.2014.10.019
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum, pp.29-36, 2009. ,
Clinical Thrombotic Manifestations in SLE Patients With and Without Antiphospholipid Antibodies: A 5-year Follow-up, Clinical Reviews in Allergy & Immunology, vol.2, issue.1, pp.131-138, 2007. ,
DOI : 10.7326/0003-4819-117-4-303
Prophylactic Antithrombotic Therapy for Patients With Systemic Lupus Erythematosus With or Without Antiphospholipid Antibodies, Archives of Internal Medicine, vol.160, issue.13, pp.2042-2050, 2000. ,
DOI : 10.1001/archinte.160.13.2042
URL : http://archinte.jamanetwork.com/data/journals/intemed/11967/ioi90546.pdf
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, Annals of the Rheumatic Diseases, vol.69, issue.01, pp.20-28, 2010. ,
DOI : 10.1136/ard.2008.101766
Hydroxychloroquine??: une nouvelle approche th??rapeutique des manifestations thrombotiques du syndrome des antiphospholipides, La Revue de M??decine Interne, vol.31, issue.12, pp.854-861, 2010. ,
DOI : 10.1016/j.revmed.2010.08.018
Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients, Annals of Internal Medicine, vol.117, issue.4, pp.303-311, 1992. ,
DOI : 10.7326/0003-4819-117-4-303
A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome, New England Journal of Medicine, vol.349, issue.12, pp.1133-1141, 2003. ,
DOI : 10.1056/NEJMoa035241
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)1, Journal of Thrombosis and Haemostasis, vol.68, issue.5, pp.848-53, 2005. ,
DOI : 10.1001/jama.291.5.576
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum, pp.1487-95, 2007. ,
A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism, New England Journal of Medicine, vol.340, issue.12, pp.901-908, 1999. ,
DOI : 10.1056/NEJM199903253401201
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism, New England Journal of Medicine, vol.360, issue.18, pp.1851-61, 2009. ,
DOI : 10.1056/NEJMoa0900241
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, vol.118, issue.17, pp.4714-4722, 2011. ,
DOI : 10.1182/blood-2011-03-340232
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, vol.101, issue.5, pp.1827-1859, 2003. ,
DOI : 10.1182/blood-2002-02-0441
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum, pp.29-36, 2009. ,
14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends, 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends, pp.685-96 ,
DOI : 10.1016/j.autrev.2014.01.053
A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome, Arthritis & Rheumatism, vol.12, issue.2, pp.464-71, 2013. ,
DOI : 10.1191/0961203303lu409oa
Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: Analysis of 24 cases from the bibliography review, Medicina Cl??nica (English Edition), vol.144, issue.3, pp.97-104, 2015. ,
DOI : 10.1016/j.medcle.2015.05.012
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial, The Lancet Haematology, vol.3, issue.9, pp.426-436, 2016. ,
DOI : 10.1016/S2352-3026(16)30079-5
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial, Lupus, vol.95, issue.3, pp.301-307, 2016. ,
DOI : 10.1111/jth.12264
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome, Clinical and Applied Thrombosis/Hemostasis, vol.3, issue.1, pp.239-286 ,
DOI : 10.1016/j.jbi.2008.08.010
Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors, Autoimmunity Reviews, vol.6, issue.2, pp.72-77, 2006. ,
DOI : 10.1016/j.autrev.2006.06.007
Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin, Clin Exp Rheumatol. 2012, vol.30, issue.3, pp.409-422 ,
Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab, Autoimmunity Reviews, vol.12, issue.11, pp.1085-90, 2013. ,
DOI : 10.1016/j.autrev.2013.05.004
Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab, Arthritis & Rheumatism, vol.362, issue.8, pp.2719-2742, 2012. ,
DOI : 10.1056/NEJMc0910965
Efficacy of Eculizumab in a Patient With Immunoadsorption-Dependent Catastrophic Antiphospholipid Syndrome, Medicine, vol.93, issue.26, p.143, 2014. ,
DOI : 10.1097/MD.0000000000000143
36-Year-Old Female with Catastrophic Antiphospholipid Syndrome Treated with Eculizumab: A Case Report and Review of Literature, Case Reports in Hematology, vol.2014, p.704371, 2014. ,
DOI : 10.1182/blood-2005-03-1319
Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome, JCR: Journal of Clinical Rheumatology, vol.21, issue.6, pp.311-314, 2015. ,
DOI : 10.1097/RHU.0000000000000290
Heparin Treatment in Antiphospholipid Syndrome With Recurrent Pregnancy Loss, Obstetrics & Gynecology, vol.115, issue.6, 2010. ,
DOI : 10.1097/AOG.0b013e3181deba40
Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression, Rheumatology, vol.49, issue.2, pp.281-289, 2010. ,
DOI : 10.1093/rheumatology/kep373
The Toll gene of Drosophila, required for dorsalventral embryonic polarity, appears to encode a transmembrane protein. Cell, pp.269-79, 1988. ,
The Dorsoventral Regulatory Gene Cassette sp??tzle/Toll/cactus Controls the Potent Antifungal Response in Drosophila Adults, Cell, vol.86, issue.6, pp.973-83, 1996. ,
DOI : 10.1016/S0092-8674(00)80172-5
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature, vol.254, issue.6640, pp.394-401, 1997. ,
DOI : 10.1126/science.1925582
Toll-like receptors on the fork roads between innate and adaptive immunity, Human Immunology, vol.72, issue.12, pp.1188-93, 2011. ,
DOI : 10.1016/j.humimm.2011.08.015
Toll-like receptors, Curr Protoc Immunol, vol.109, pp.14-26, 2015. ,
DOI : 10.1002/0471142735.im1412s109
Toll-like r??cepteurs, Pathologie Biologie, vol.57, issue.5, pp.430-438, 2009. ,
DOI : 10.1016/j.patbio.2008.04.003
Signalling pathways and molecular interactions of NOD1 and NOD2, Nature Reviews Immunology, vol.1029, issue.1, pp.9-20, 2006. ,
DOI : 10.4049/jimmunol.170.3.1406
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling, Nature Reviews Immunology, vol.19, issue.5, pp.353-64, 2007. ,
DOI : 10.4049/jimmunol.175.2.839
Toll-like receptor downstream signaling, Arthritis Research & Therapy, vol.7, issue.1, pp.12-21, 2005. ,
DOI : 10.1186/ar1469
The role of Toll-like receptors in chronic inflammation, The International Journal of Biochemistry & Cell Biology, vol.42, issue.4, pp.506-524 ,
DOI : 10.1016/j.biocel.2009.10.009
Direct and indirect role of Toll-like receptors in T cell mediated immunity, Cell Mol Immunol, vol.1, issue.4, pp.239-285, 2004. ,
The structural basis of lipopolysaccharide recognition by the TLR4???MD-2 complex, Nature, vol.50, issue.7242, pp.1191-1196, 2009. ,
DOI : 10.4049/jimmunol.181.2.1245
Essential role of MD-2 in LPS responsiveness and TLR4 distribution, Nature Immunology, vol.7, issue.7, pp.667-72, 2002. ,
DOI : 10.1038/sj.gt.3301206
Toll receptors in innate immunity, Trends in Cell Biology, vol.11, issue.7, 2001. ,
DOI : 10.1016/S0962-8924(01)02004-9
Modulating vaccine responses with dendritic cells and Toll-like receptors, Immunological Reviews, vol.171, issue.1, pp.227-50, 2004. ,
DOI : 10.1038/ni962
Immunobiology of Dendritic Cells, Annual Review of Immunology, vol.18, issue.1, pp.767-811, 2000. ,
DOI : 10.1146/annurev.immunol.18.1.767
Control of B-cell responses by Toll-like receptors, Nature, vol.4, issue.7066, pp.364-372, 2005. ,
DOI : 10.1016/0008-8749(72)90043-3
TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells, European Journal of Immunology, vol.176, issue.11, 2007. ,
DOI : 10.4049/jimmunol.172.5.3252
The Diploid Genome Sequence of an Individual Human, PLoS Biology, vol.17, issue.10, p.254, 2007. ,
DOI : 10.1371/journal.pbio.0050254.sd001
Role of Toll-Like Receptors in Infection and Immunity, Drugs, vol.8, issue.2, pp.15-29, 2006. ,
DOI : 10.4049/jimmunol.174.5.2942
Toll-like receptors, inflammation and cancer. Semin Cancer Biol, Feb, vol.16, issue.1, pp.32-39, 2006. ,
Toll-like receptors and cancer, Nature Reviews Cancer, vol.5, issue.1, pp.57-63, 2009. ,
DOI : 10.1182/blood-2007-05-088682
glycoprotein I interaction on endothelial cells, Lupus, vol.23, issue.12, pp.1302-1306, 2014. ,
DOI : 10.1182/blood-2011-01-333617
Toll-like receptor (TLR)-4 mediates anti-??2GPI/??2GPI-induced tissue factor expression in THP-1 cells, Clinical & Experimental Immunology, vol.185, issue.2, pp.189-98, 2011. ,
DOI : 10.4049/jimmunol.1000526
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2249.2010.04291.x/pdf
Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease, European Journal of Clinical Investigation, vol.168, issue.5, pp.328-362, 2004. ,
DOI : 10.4049/jimmunol.168.3.1435
Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product, J Immunol Baltim Md, vol.162, issue.7, pp.3749-52, 1950. ,
TLR4 upregulation at protein or gene level is pathogenic for lupus-like autoimmune disease, J Immunol Baltim Md, vol.177, issue.10, pp.6880-6888, 1950. ,
DOI : 10.4049/jimmunol.177.10.6880
URL : http://www.jimmunol.org/content/jimmunol/177/10/6880.full.pdf
Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutationinduced mouse lupus, J Immunol Baltim Md, vol.183, issue.10, pp.6207-6223, 1950. ,
Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes, Diabetologia, vol.292, issue.8, pp.1665-1673, 2009. ,
DOI : 10.1007/s00125-009-1394-8
Abstract, Endocrine Regulations, vol.15, issue.3, pp.137-181, 2017. ,
DOI : 10.1515/enr-2017-0014
A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus, Arthritis Rheumatol Hoboken NJ. 2014, vol.66, issue.7, pp.1882-1889 ,
TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1?? and caspase-1 in monocytes and dendritic cells, Immunobiology, vol.214, issue.8, pp.683-91, 2009. ,
DOI : 10.1016/j.imbio.2008.12.003
Human antiphospholipid antibodies induce TNF?? in monocytes via Toll-like receptor 8, Immunobiology, vol.215, issue.3, pp.230-271, 2010. ,
DOI : 10.1016/j.imbio.2009.03.002
Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8, Molecular Human Reproduction, vol.22, issue.7, pp.465-74 ,
DOI : 10.1093/molehr/gaw027
Traitement du syndrome des anticorps antiphospholipides, La Revue de M??decine Interne, vol.33, issue.4, pp.217-239 ,
DOI : 10.1016/j.revmed.2012.01.007
Mechanisms of Fever Production and Lysis: Lessons from Experimental LPS Fever, Compr Physiol, vol.856, issue.2, pp.1563-604, 2014. ,
DOI : 10.1111/j.1749-6632.1998.tb08311.x